profiles.stanford.edu/paul-yock

Yock also founded and is the Director of the Program in Biodesign, a unit of Bio-X dedicated to advanced training in medical technology innovation.

pubs.rsc.org/en/content/articlehtml/2016/sc/c6sc00053c

Feb 24, 2016 ... Remarkably, 8oxoG possesses an even lower oxidation potential (E1/2 = 0.74 V versus ..... On the basis of CD signatures, Tm analysis and fluorescence .... Mr Darian Blanchard (UOG, now at Aterica Health Inc., Waterloo, ON). .... J. R. Daft, K. H. Shaughnessy, J. D. Epperson and N. L. Greenbaum, Chem.

www.jimmunol.org/content/jimmunol/187/3/1243.full.pdf

The American Association of Immunologists, Inc., is published twice ... Gerald E. Byrne,† P. Leif Bergsagel,‡ John P. Shaughnessy, Jr., x. Lawrence H. .... This work was supported in part by National Institutes of Health Grants CA121044,. CA121044 .... cells were stained with CD11b–PE plus annexin V–FITC plus 7- amino-.

onlinelibrary.wiley.com/doi/full/10.1002/hep.29500

Oct 1, 2017 ... 1Gastroenterology and Hepatology, University of Tennessee Health Science .... A previously identified biopsy gene signature (Bohne et al, JCI ..... Total economic savings of HCV GT1 treatment with DAAs (vs. ...... Melissa Shaughnessy ‐ Employment: Merck & Co., Inc.; Stock Shareholder: Merck & Co., Inc.